期刊文献+

糖皮质激素和丙种球蛋白治疗川崎病对照分析 被引量:4

下载PDF
导出
摘要 目的:探讨糖皮质激素(GCS)在川崎病(Kawasaki disease,KD)患儿治疗中的应用。方法:回顾性分析GCS加阿司匹林治疗22例KD住院患儿(A组)的临床资料;选择同期人血丙种球蛋白(IVIG)加阿司匹林治疗KD住院患儿22例(B组),对照两组疗效及冠状动脉受损情况。结果:两组热退时间、炎症指标恢复情况、冠状动脉病变发生率差异均无统计学意义。结论:GCS加阿司匹林治疗KD并无不妥,经济且安全有效。
出处 《温州医学院学报》 CAS 2011年第2期179-180,共2页 Journal of Wenzhou Medical College
  • 相关文献

参考文献7

二级参考文献47

  • 1于宪一.川崎病治疗的现状和展望[J].实用儿科临床杂志,2004,19(11):922-924. 被引量:42
  • 2杜军保.进一步提高川崎病的临床诊疗水平[J].中华儿科杂志,2006,44(5):321-323. 被引量:96
  • 3Tsuda E, Kamiya T,Ono Y, et al. Incidence of stenotic lesions predicted by acute phase changes in coronary [ J ]. Pediatr Cardiol,2005,26: 73 - 79.
  • 4Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome [ J ]. N Engl J Med,1991, 324:1633 - 1639.
  • 5Durongpisikul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatent in Kawasaki disease[J ]. Pediatr Cardiol, 2003,24:145 - 148.
  • 6Fong NC, Hui YW, Li CK, et al. Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness [J ]. Pediatr Cardiol, 2004, 25: 31-34.
  • 7Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment of treatment on coronary involvement [J]. Pediatrics, 1979,62:175 - 179.
  • 8Kusakawa S. Long- term administrative care of Kawasaki disease[J]. Acta PediatrJap, 1983,25:205- 209.
  • 9Jane WN. Treatment of Kawasaki disease: corticosteroids revisited[J]. J Pediatr, 1999,135:411 - 413.
  • 10Makoto S, Katsubiko S, Takesbi T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease [J]. J Pediatr,1999,125: 465 - 469.

共引文献656

同被引文献57

  • 1Senzaki H.Long-term outcome of Kawasaki disease[J].Circulation, 2008, 118(25) : 2763-2772.
  • 2Benseler S M, McCrindle B W, Silverman E D, et al.Infections and Kawasaki disease: implications for coronary artery outcome[J].Pediatrics, 2005, 116(6): 760-766.
  • 3Suenage T, Suzuki H, Shibuta S, et al.Deteetion of multiple superantigen genes in stools of patients with kawaski disease[J].J Pediatr, 2009,155(2): 266-270.
  • 4Matsubara K, Fukaya T.The role of superantigens of group A streptococcus and staphylococcus anreus in Kawasaki disease[J].Curr Opin Infect Dis, 2007, 20(3): 298-303.
  • 5Rowett D, Sroeks N, Jaekowski L.Reducing the risk of adverse thrombotic events : the role of asprin and elopidogrel[J].AustrMian Family Physician, 2008, 37(9): 721-726.
  • 6Muta H, Ishii M, Yashiro M, et al.Late intravenous immunoglobulin treatment in patients with Kawasaki disease[J].Pediatrics, 2012, 129(2): 291-297.
  • 7Portman M A, Olson A, Soriano B, et al.Etanerept as adjunctive treatment for acute Kawasaki disease: study design and rationale[J].Am Heart, 2011, 161(3): 494--499.
  • 8Son M B, Gauvreau K, Burns J C, et al.Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospectivestudy[J].J Pediatr, 2011, 158(4): 644-649.
  • 9杨晓光.甲基强的松龙治疗难治性川崎病26例疗效观察[J].当代医学,2009,15(2):1-3. 被引量:6
  • 10王建新,邱婷婷.丹参生脉饮加味治疗川崎病恢复期综合征60例的临床研究[J].时珍国医国药,2009,20(8):2073-2074. 被引量:4

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部